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Duchenne muscular dystrophy (DMD) is one of the most common 
and severe of the inherited dystrophies, with an incidence of 1 in 
3 500 live, male births worldwide. Long before the discovery of 
the DMD gene, early investigators noted the X-linked recessive 
heritability of DMD by scrutiny of affected family pedigrees.[1] The 
allelic form of DMD, Becker muscular dystrophy (BMD), has a lower 
incidence of 1:14 000 - 18 000 boys, a milder progression and longer 
life expectancy.[2]
Over the last two decades, better understanding of the underlying 
disease aetiology as well as major advances in medical technology 
have brought about significantly improved genetic diagnosis and 
clinical care for B/DMD patients. However, a cure, while in sight, 
remains elusive. This said, exciting developments in the field of gene-
based therapies have once again put B/DMD in the limelight, with 
renewed focus on the importance of comprehensive genetic testing 
protocols. We present a historical overview of the medical service for 
B/DMD in South Africa (SA), specifically in the Western Cape, from 
a clinical as well as a genetic perspective.
Clinical description
DMD manifests in boys between 2 and 5 years of age, with delayed 
motor milestones and symptoms such as frequent falling, difficulty 
in getting up, gait problems and toe walking. Pseudohypertrophic 
calves, lumbar lordosis and weakness of the neck flexors are typical. 
Weakness of the knee and hip extensors results in the Gower’s 
manoeuvre, where the child uses his hands and arms to ‘climb’ up his 
body to rise from a prone position. Muscle weakness is progressive, 
with loss of independent ambulation between 9 and 13 years of age 
for DMD and >16 years for BMD patients. Previously, death before 
the age of 19 years from respiratory and cardiac complications was 
common, but current multidisciplinary care allows survival into 
adulthood. Rare cases have a very localised disease expression, e.g. 
cardiac disease. A degree of intellectual disability is seen in over a 
third of the affected children.[3] BMD patients have a more diverse 
presentation and progression, in some cases showing only mild 
myalgia and muscle cramps with no weakness.[4] 
B/DMD genetics
Localisation of the DMD gene to Xp21 was achieved by cytogenetic 
studies of DMD-manifesting females carrying X-autosome 
translocations and extensive work with positional cloning.[5] Full 
characterisation of the gene revealed 2.4Mb of genomic sequence and 
a 14kb mRNA transcript, making it one of the largest known human 
genes, comprising 79 exons, at least 8 tissue-specific promoters and 
2 polyA-addition sites. Owing to its large size, the DMD gene is 
prone to mutations, of which approximately 70% are exonic deletions 
and duplications. These tend to cluster within two hot-spot regions 
spanning exons 44 - 53 and exons 2 - 20. The remaining 25 - 35% 
of the disease-associated changes are small/point alterations, mostly 
nonsense, frame-shift or splice site mutations.[6] These do not appear 
to exhibit any clustering effect and because of the large size of the 
gene, continue to present a diagnostic challenge.
A full-length dystrophin is a large, rod-like cytoskeletal protein 
localised to the inner surface of muscle fibres, bridging the inner 
cytoskeleton (F-actin) and the extracellular matrix, providing 
structural integrity to the muscle cell membrane.[7] Two main factors 
appear to influence severity of the B/DMD phenotype: localisation 
of the causative mutation within the gene relative to the dystrophin 
critical functional domains; and the disruption/maintenance of 
the translational open reading frame (ORF). The ‘reading frame 
hypothesis’ which fits ~90% of DMD cases, argues that ORF-
disrupting mutations cause premature termination of translation and 
nonsense-mediated decay (NMD), resulting in complete absence of 
dystrophin and a more severe phenotype. Mutations affecting the 
actin-binding N-terminus, the carboxy-terminus and the cysteine-
rich regions of dystrophin generally cause a severe phenotype, even 
if the rearrangement is in-frame. The central and distal rod domains, 
however, appear to be almost dispensable and cases of in-frame 
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deletions of approximately half of the gene have been described, with 
only a mild effect on the phenotype.[8] However, phenotypes can vary 
between patients carrying identical mutations even within one family, 
which could be a result of the mutation’s epigenetic context.[6] The 
schematic overview in Fig. 1 reflects general findings for in-frame 
deletions. 
B/DMD in South Africa: The early 
days
The clinical database and DNA registry in the Division of Human 
Genetics at the University of Cape Town (UCT), were the first under-
takings of a genetic service for B/DMD in SA. This was supported 
by the neuromuscular clinic at Red Cross War Memorial Children’s 
Hospital (RCWMCH) and numerous genetic outreach clinics spear-
headed by Prof. Peter Beighton.
In 1987, Prof. Beighton and his team of clinicians and scientists 
set out to determine the feasibility of implementing a genetic 
testing service for B/DMD. Southern blot (SB) analysis using DNA 
probes targeting the DMD locus became the first molecular genetic 
test offered in SA. SB remains the gold standard methodology 
for a number of genetic disorders, but it is a laborious and 
expensive technique with an extended turn-around time, as well 
as health and safety risks relating to the use of radioactivity. This 
analytical approach to B/DMD changed in the early 1990s when 
the polymerase chain reaction (PCR) launched molecular biology 
into a new era. The deletion hot-spots within the DMD gene 
could now be screened using multiplex PCR (mPCR) and agarose 
gel electrophoresis. Identification of the causative deletion in a 
proband confirmed the diagnosis and provided genetic closure 
to the family, enabling effective prenatal analysis and genetic 
counselling for future reproductive choice. The shortcoming of 
the mPCR, however, was its inability to detect duplications or 
deletions outside of the hot-spots, nor was it capable of detecting 
deletions in carrier females, due to the contribution from the 
normal X chromosome. The female B/DMD carrier status was still 
determined by restriction enzyme fragment length polymorphism 
analysis. In due course, this was replaced by microsatellite linkage 
studies with fluorescent PCR and capillary gel electrophoresis. 
In the absence of an identifiable mutation, however, the 5% 
uncertainty linked to meiotic recombination even today presents a 
reporting and genetic counselling challenge. 
During the period of 1987 - 1992, exonic deletions were identified 
in 50% of Indian, white and coloured patients.[9] In contrast, only 
22% of black patients had identifiable deletions. This was thought to 
suggest that unique mutations, not detectable by methods used at the 
time, might be more frequent in the black patients compared with 
other populations. It was also thought to explain the overall low B/
DMD prevalence in SA (1:40 000), compared with that in the UK.[9] 
The increased DMD frequency in the Indian patients was found to 
be in line with findings reported from the UK. This observation 
prevails, though information relating to mutation prevalences in the 
SA population groups is not easily gathered from the diagnostic test 
requests, as the patients’ ethnicity is generally not provided. 
The service today
Genetic testing for B/DMD in the SA public sector is currently 
performed within the National Health Laboratory Service (NHLS) 
in Cape Town (Groote Schuur Hospital) and Johannesbsurg, and is 
extended to the State as well as private patients in and outside of SA. 
The mPCR method has since been replaced by the multiple ligase-
dependent probe amplification (MLPA) assay, though microsatellite 
linkage analysis is still available for families with no identified 
mutations. Introduction of the MLPA in 2007 was a significant 
improvement to the service, not only because of its coverage of all the 
exons within the DMD gene, but also due to its dosage component, 
which enables identification of duplications in males and determines 
B/DMD carrier status in females (Fig. 2). 
Since its inception in 1987, over 790 B/DMD families and 2 000 
individuals have been referred for testing to the diagnostic genetic 
service in Cape Town. Of those, 1 264 individuals were referred 
for linkage analysis, as the only testing methodology available 
in the early days (these figures therefore include a number of 
unaffected family members). Implementation of the MLPA in 2007 
significantly improved mutation detection rate from ~30% to 45%. 
A similar pick-up rate has been reported in both Cape Town and 
Johannesburg laboratories, with a similar distribution of deletions 
(~36%) and duplications (9%).[10] This could be viewed as relatively 
low, compared with the internationally published mutation fre-
quencies.[6] However, it must be borne in mind that test requests 
are received from across southern Africa, often from regions 
with limited access to specialised diagnostic tools. Therefore, in 
addition to those patients who carry mutations other than exonic 
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Fig. 1. Correlation between the location of in-frame deletions and the BMD or DMD phenotype. (A) Schematic drawing of the dystrophin protein with its 
functional domains. The location of the different exons is shown underneath the protein. (B) Graphic overview of the relation between the location of in-frame 
deletions and the severity of the phenotype (adapted from Aartsma-Rus, et al.[6]).
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rearrangements (which are not detected with the MLPA), a number 
may require a clinical reassessment. Interestingly though, only 
about 50% of the definitively diagnosed B/DMD patients attending 
the dedicated neuromuscular clinic at RCWMCH carry exonic 
rearrangements, which is lower than expected and bears further 
investigation. 
Because of its large size, testing for small/point mutations in 
the DMD gene is challenging and has not yet become part of 
the routine diagnostic repertoire of the NHLS laboratories. High-
resolution melting curve analysis (HRM) for small/point mutation 
detection was successfully attempted locally and the results were 
published by Esterhuizen et al.[11] However, HRM in B/DMD has 
been superseded by next-generation sequencing (NGS)[12] which is 
currently undergoing validation in the Division of Human Genetics 
at UCT and the NHLS in Cape Town. Fig. 3 depicts the ideal 
workflow for a laboratory diagnosis of B/DMD, ultimately aiming at 
determining eligibility for gene-based therapy. RNA-based mutation 
analysis is not incorporated into the current laboratory protocols 
due to its limited benefit at this time. However, future availability of 
gene-based therapies may change this, as the downstream effects of a 
mutation are better discerned from muscle RNA. 
Clinical practice
A dedicated neuromuscular service has been in existence at the 
RCWMCH for >20 years. Referrals are predominantly from the 
Western Cape, but children from further afield, including other 
African countries, are also seen. B/DMD is the predominant 
neuromuscular condition managed, with >90 B/DMD children 
seen to date. In keeping with international protocols, the diagnosis 
in clinically suspected cases is confirmed by DNA analysis and 
if negative, by immunohistochemical (IHC) staining of muscle 
biopsies, unless a genetic diagnosis was previously made in a 
family member or if the child is medically unstable.[13] Clinic visits 
are scheduled every 3 - 6 months, where the families have access 
to genetic counselling and support from the Muscular Dystrophy 
Foundation of SA (MDFSA).[14] 
After result delivery and genetic counselling, patients are managed 
according to the international guidelines within the capacity of the 
service facilities.[3,13] A resident physiotherapist liaises with the ancillary 
support in the community, special schools and private therapists 
regarding interventions such as stretches, chest physiotherapy and 
orthotic devices (e.g. nocturnal ankle foot orthoses and wheelchairs). 
General health and power scores are serially recorded, including 
the presence of Gower’s manoeuvre and evidence of contracture 
formation. 
All children undergo regular cardiac assessments and receive enalapril 
or an equivalent agent as prophylaxis. Basic respiratory screens are 
performed at each clinic visit, and the patients and carers are educated 
with regard to good respiratory care and the use of devices such as the 
cough-assist. Corticosteroid intervention is commenced as soon as motor 
function appears affected (usually by 4 years of age). As corticosteroid 
side-effects include immunosuppression, prior to treatment children 
are vaccinated against varicella (Varilrix; GlaxoSmithKline, Belgium) 
and undergo testing to exclude tuberculosis. Subsequent monitoring for 
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Fig. 2. MLPA dosage analysis of a DMD-affected boy with a deletion of exons 42 and 43 (top diagram) and his DMD-carrier mother (dosage ratio <0.6) using 
the Coffalyser.NET software (MRC-Holland, the Netherlands).
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complications relating to chronic corticosteroid 
use includes annual bone mineral density 
assessments. Intercurrent infections are treated 
aggressively and patients are vaccinated against 
pneumococcus and influenza. Ambulatory 
devices for wheelchair-dependent children are 
reviewed at each clinic visit, and formal seating 
assessments are coordinated in specialist 
settings. Patients with scoliosis are referred 
to orthopaedic specialists. Bi-level positive 
airway pressure (BPAP) support for nocturnal 
hypoventilation is commenced following 
confirmation with polysomnography. 
Schooling and education support runs 
in parallel with clinic care, which promotes 
placement of B/DMD patients in schools 
with appropriate facilities. As they mature, 
the children also need emotional support 
to deal with their illness. This is partially 
addressed through the service but a great 
deal of support is accessible to the patients 
and their families through (MDSFA).[14] 
As a direct result of this multidisciplinary 
approach, B/DMD patients are surviving 
longer. While the significance of this 
extended lifespan cannot be discounted, the 
main aim is to ensure the best possible quality 
of life for the child and his (sometimes her) 
family. Many of the children demise through 
the course of their progressive disease, but 
an increasing number are growing beyond 
the capacity of a children’s service to manage. 
The RCWMCH team are actively involved 
in interfacing with adult services and 
developing platforms for transition of care.
Into the future
Genetic therapies
The approaches to the development of 
genetic therapies can be roughly divided into 
two main fields: gene replacement and gene 
modification. Gene replacement strategies 
(viral vectors, utrophin up-regulation, myo-
blast and stem cell transplantation) aim 
at delivery of a normal copy of the gene 
directly to the affected tissue, either as 
naked DNA in a viral vector, or as a gene 
copy in a myoblast or stem cell. Proof-of-
principle experiments on animal models 
(the mdx mouse) have been conducted and 
demonstrate that dystrophin expression can 
be restored to varying degrees to single 
muscles, muscle groups (limbs) or the entire 
body.[15] The major advantage of this strategy 
is that it can be applied to patients regardless 
of the underlying mutations. Although the 
research is showing promise, much work 
still needs to be done to overcome the 
mechanical and practical difficulties of gene 
delivery to the muscles, the immunological 
concerns and the high cost. 
The other approach to genetic therapy, i.e. 
gene modification, also referred to as mutation- 
or gene-based therapy, is currently receiving 
much attention. In terms of its application and 
delivery, this approach is viewed as less fraught 
with difficulties and significantly cheaper than 
gene replacement. Effectively, as identification 
of the particular mutation is the basis for 
this approach, ‘personalised gene therapy’ is 
becoming a reality. 
At this time, closest to clinical application 
are the stop codon read-through and exon 
skipping therapies, which aim to restore 
the ORF and affect production of partially 
functional dystrophin, thereby ameliorating 
the severe Duchenne to a milder Becker 
phenotype. The stop codon read-
through agent, ataluren (Translarna; TC 
Therapeutics, USA), has recently received 
a conditional marketing authorisation from 
the European Medicines Agency (EMA) 
for use in ambulant Duchenne patients >5 
years of age. PTC Therapeutics have also 
announced commencement of a rolling 
submission of a new drug application (NDA) 
to the US Food and Drug Administration 
(FDA).[16] Similarly, intensive effort is made 
to demonstrate the safety and efficacy of 
exon skipping therapy for exon 51, which has 
shown considerable promise in phase II and 
III clinical trials. In October 2014, Prosensa 
Therapeutics announced that the FDA had 
given drisapersen (an exon skipping agent 
for exon 51) a fast track designation.[17-19] 
Registries and databases 
In 2010, the Division of Human Genetics 
at UCT obtained ethical approval for a 
formal repository entitled Genetics of Becker/
Duchenne Muscular Dystrophy: Biological 
Material Repository Including Database, by 
the UCT Faculty of Health Sciences Research 
Ethics Committee (HREC Ref. 234/2010). 
The repository holds all DNA material 
obtained through research and diagnostic 
testing for B/DMD, which may be needed for 
further work-up and/or B/DMD research.
In anticipation of a therapy-driven demand 
for the delineation of disease-causing genetic 
mutations, the neuromuscular service at 
RCWMCH, in collaboration with the Division 
of Human Genetics at UCT, is collating a 
database listing all patients with a clinical 
diagnosis of B/DMD currently attending 
the neuromuscular clinic at RCWMCH 
(HREC Ref. 013/2013). The database holds 
information relating to each patient’s clinical 
presentation, diagnosis, treatment, results of 
genetic testing, muscle biopsy sampling, etc., 
Clinical
presentation,
CPK, ‘etc.’
DEL/DUP testing
(MLPA)
Dystrophin
straining
DEL/DUP POS
Muscle for
RNA proling
Bioinformatics
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Fig. 3. A diagrammatic representation of a workflow for a genetic diagnosis and mutation character-
isation in B/DMD. Blue fields: positive MLPA findings (exonic deletions or duplications) are analysed 
for their effect on the ORF (frame-checker), followed by genotype-phenotype correlation, e.g. inter-
ruption of the ORF should result in a more severe phenotype, etc. If this is concordant, a report can be 
issued. In discordant cases, a muscle biopsy for RNA testing and further bioinformatics analyses may 
be pursued before issuing a final result and determining eligibility for gene-based therapy. Green fields: 
Patients with negative MLPA results (no deletions or duplications) should be tested for small/point 
mutations using DNA sequencing (NGS and/or Sanger). Based on the outcome, a report may be issued 
or further bioinformatics analysis may be indicated. RNA testing of muscle biopsy material could be 
pursued directly, which will also detect intronic variants, i.e. pseudo-exon mutations. Further testing for 
copy number variations, e.g. array CGH, may be performed in patients with possible contiguous gene 
syndrome (plus phenotype). (CPK = creatine phosphokinase; DEL/DUP = deletion/duplication; CGH = 
comparative genomic hybridisation; GENO-PHENO = genotype-phenotype correlation.)
S71       June 2016, Vol. 106, No. 6 (Suppl 1)
THE NEW MILLENNIUM
ultimately serving as a repository of information to identify DMD 
patients who may be suitable for a mutation-based intervention, as 
well as providing a source of information for future clinical trials, 
research and publication. The database currently holds information 
on 93 patients and is modelled on the TREAD-NMD database, an 
international care and site registry created to facilitate clinical research 
for neuromuscular diseases.[20,21] Families are updated at each clinic 
visit of the stage of the data collection and how it relates to a potential 
gene therapy option. International liaison is also in place to ensure 
there is consistency in the patient selection as potential candidates for 
intervention. 
Research 
Traditionally, research into the genetics of B/DMD conducted at UCT/
RCWMCH has been focused on the translational aspects of mutation 
detection and diagnostic testing. Over the years, much of this research 
was funded by the MDFSA, whose collaborative ties with UCT go back 
to 1974, when Prof. Peter Beighton was elected onto the first national 
MDFSA executive committee. This relationship has continued with 
various members of the Division of Human Genetics serving on the 
MDFSA committees and medical advisory boards. 
Funded by the NHLS Research Trust, current genetic research at 
UCT/RCWMCH includes a project investigating dystrophin express-
ion in human melanocytes to determine whether a less-invasive skin 
biopsy (and melanocyte culture) could replace muscle biopsy sampling 
for RNA-based confirmation and molecular diagnosis of B/DMD.[22] 
Also underway is validation of NGS as a diagnostic methodology for 
small/point mutation detection in B/DMD.
From a clinical perspective, understanding the phenotypic (and 
genetic) profile of the SA patient population is important for a strategic 
and focused approach to care. Clinical studies have been conducted 
to assess the neurocognitive profile of the RCWMCH B/DMD patient 
cohort.[23] Currently conducted at RCWMCH is a study analysing 
phenotypic data of all the B/DMD patients attending the RCWMCH 
muscle clinic, using multivariate regression and longitudinal analysis 
of variables ranging from the time of presentation, to cardiac and 
respiratory complications, to eventual loss of ambulation. This, in relation 
to the causative genetic defect, is aimed at better understanding of the 
genotype-phenotype correlations in local B/DMD patients, as compared 
with the internationally published data.[4-6] In due course, the database 
should be expanded to enable participation and data entry by clinicians 
from multiple centres, producing a more nationally representative B/
DMD data repository and a potentially useful diagnostic/prognostic tool. 
Conclusion
The DMD gene was one of the first genes identified at the start of the 
molecular genetic era. The clinical and genetic service for B/DMD at 
UCT and RCWMCH was the first of its kind in SA and has evolved 
in line with international practice, even though it still incorporates 
the unique needs of children in SA. Today’s clinicians and scientists 
continue to build on the foundations laid by the pioneering work 
of Prof. Beighton and his peers. The new era of genetic therapies 
and precision medicine presents exciting therapeutic options for 
patients and families, as well as areas of further research for scientists 
and clinicians. Thus, despite the challenges of a resource-limited 
setting, our research and data management efforts continue to strive 
towards better care and, one day soon, successful treatment, not just 
management, of B/DMD and its symptoms. 
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